-+ 0.00%
-+ 0.00%
-+ 0.00%

HSBC Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $880

Benzinga·07/06/2026 18:54:20
Listen to the news
HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $990 to $880.